Bio-Rad Laboratories, Inc. BIO
Composite 56/100; the shares have moved about 39% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Quality ranks 34/100 — a moderate mark against it.
Balance-sheet strength ranks 88/100 — a strong point in its favour. Momentum ranks 75/100 — a strong point in its favour. Growth ranks 54/100 — a slight point in its favour.
Quality ranks 34/100 — a moderate mark against it. Valuation ranks 41/100 — a slight mark against it.
What the company does Bio-Rad Laboratories develops and markets life science research tools and clinical diagnostic systems used for protein/nucleic-acid analysis, bioprocess quality control, food safety, and transfusion testing across academic, biopharma, and clinical labs worldwide.
Key financials Gross margin 52%, operating margin 5.8%, net margin 6.5%. ROE 2.5%, ROA 1.8%, ROCE 3.1%. Revenue growth 1.1%, EPS down 83%. Debt/equity 0.20, current ratio 3.21, interest coverage 5.51.
Stock health Sideravia overall score 45.9 (weak quality, rich valuation). Strength pillar 84.5, momentum 61.0, valuation percentile 38.3. RSI(14) 68.10; -4.78% from 52-week high.
Price vs fair value Bio-Rad trades at a PREMIUM of 56.80% versus our fair-value estimate and a PREMIUM of 9.10% versus the analyst 12-month target. - Fair-value gap persists despite modest revenue growth (1.1%) and steep EPS decline (-83.0%) (company filings). - Analyst target 297 implies 9.10% upside from current 326.72 (analyst count 5.0). - Sideravia valuation percentile 38.3 indicates rich pricing relative to screened universe (Sideravia). - Recent momentum (+29.34% over 12m) may support premium despite weak profitability metrics (momentum data).
Looking forward Forward P/E 35.59 and PEG 0.76 suggest earnings recovery is priced in; execution on bioprocess and diagnostics segments will be key to justify valuation.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-05, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.